Management of Psoriasis With Topicals: Applying the 2020 AAD-NPF Guidelines of Care to Clinical Practice.
Cutis
; 110(2 Suppl): 8-14, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-36219602
ABSTRACT
Topical medications have high utility in the treatment of psoriasis because of their localized effect and ability to be used as both monotherapy and adjunctive therapy. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation (NPF) published guidelines in 2020 regarding the management of psoriasis with topical therapies. These guidelines are a framework that assist clinicians treating psoriasis patients with topical agents including steroids, calcineurin inhibitors (CNIs), vitamin D analogues, retinoids (tazarotene), emollients, keratolytics (salicylic acid), anthracenes (anthralin), and keratoplastics (coal tar). This review presents these evidence-based recommendations in a form that dermatologists can readily apply to their clinical practice. The selection of an appropriate topical therapy, effective combination therapies, duration of use, and adverse events are addressed.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Alcatrão
/
Fármacos Dermatológicos
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article